Biotechnology for a Conservative Japanese Drug Industry
Executive Summary
Japanese drug companies remain high conservative, reluctant to expand beyond a national or regional focus to create worldwide pharmaceutical businesses. More are turning to biotech collaborations to provide new products, particularly favoring combinatorial chemistry deals which are relatively inexpensive and have short-term payoffs.